disopyramide has been researched along with Wolff-Parkinson-White Syndrome in 31 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
Wolff-Parkinson-White Syndrome: A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This is the first case report of preterm labor and abruptio placentae following the administration of disopyramide during pregnancy." | 7.70 | Preterm labor and accidental hemorrhage after disopyramide therapy in pregnancy. A case report. ( Abbi, M; Kriplani, A; Singh, B, 1999) |
| "In the aim of determining an electrophysiologic effect of disopyramide and metoprolol at alone therapy and in combination in patients with supraventricular tachycardia on the background of Wolff-Parkinson-White syndrome 23 persons were examined." | 7.69 | Comparative analysis of electrophysiologic effect of metoprolol and disopyramide, acting alone or in combination in patients with supraventricular tachycardia and Wolff-Parkinson-White syndrome. ( Bobrov, VA; Frolov, AI; Galichansky, IV; Mitchenko, EI, 1994) |
| "Disopyramide was administered intravenously to 54 patients during atrial fibrillation and predominantly pre-excited QRS configuration at the time of electrophysiologic study." | 7.67 | Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome. ( Fujimura, O; Klein, GJ; Sharma, AD; Szabo, T; Yee, R, 1989) |
| "We evaluated the electrophysiologic effects of disopyramide phosphate in 12 patients with the Wolff-Parkinson-White syndrome." | 7.66 | Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome. ( Cook, L; Gallagher, JJ; Kerr, CR; Prystowsky, EN; Smith, WM, 1982) |
| "By means of intracardiac recordings and programmed electrical stimulation of the heart, the combination effect of verapamil and disopyramide on induction of circus movement tachycardia was studied in 8 patients with anomalous extranodal atrioventricular (A-V) pathway." | 7.66 | Combined effect of verapamil and disopyramide on induction of circus movement tachycardia in patients with pre-excitation. ( Kawai, C; Konishi, T; Matsuda, H; Matsuyama, E; Tamamura, T, 1981) |
| "The effect of administration of disopyramide on the ventricular response to atrial fibrillation was studied in six patients with the Wolff-Parkinson-White syndrome." | 7.66 | Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. ( Bennett, DH, 1978) |
| "Disopyramide was first infused intravenously at 1 mg kg-1 for 5 min followed by a continuous infusion at 0." | 5.28 | Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White syndrome. ( Aihara, N; Kamakura, S; Kurita, T; Matsuhisa, M; Ohe, T; Shimizu, W; Shimomura, K; Takaki, H, 1992) |
| " This is the first case report of preterm labor and abruptio placentae following the administration of disopyramide during pregnancy." | 3.70 | Preterm labor and accidental hemorrhage after disopyramide therapy in pregnancy. A case report. ( Abbi, M; Kriplani, A; Singh, B, 1999) |
| "In the aim of determining an electrophysiologic effect of disopyramide and metoprolol at alone therapy and in combination in patients with supraventricular tachycardia on the background of Wolff-Parkinson-White syndrome 23 persons were examined." | 3.69 | Comparative analysis of electrophysiologic effect of metoprolol and disopyramide, acting alone or in combination in patients with supraventricular tachycardia and Wolff-Parkinson-White syndrome. ( Bobrov, VA; Frolov, AI; Galichansky, IV; Mitchenko, EI, 1994) |
| "Disopyramide was administered intravenously to 54 patients during atrial fibrillation and predominantly pre-excited QRS configuration at the time of electrophysiologic study." | 3.67 | Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome. ( Fujimura, O; Klein, GJ; Sharma, AD; Szabo, T; Yee, R, 1989) |
| "We evaluated the electrophysiologic effects of disopyramide phosphate in 12 patients with the Wolff-Parkinson-White syndrome." | 3.66 | Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome. ( Cook, L; Gallagher, JJ; Kerr, CR; Prystowsky, EN; Smith, WM, 1982) |
| "By means of intracardiac recordings and programmed electrical stimulation of the heart, the combination effect of verapamil and disopyramide on induction of circus movement tachycardia was studied in 8 patients with anomalous extranodal atrioventricular (A-V) pathway." | 3.66 | Combined effect of verapamil and disopyramide on induction of circus movement tachycardia in patients with pre-excitation. ( Kawai, C; Konishi, T; Matsuda, H; Matsuyama, E; Tamamura, T, 1981) |
| "The effect of administration of disopyramide on the ventricular response to atrial fibrillation was studied in six patients with the Wolff-Parkinson-White syndrome." | 3.66 | Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. ( Bennett, DH, 1978) |
| "Disopyramide phosphate was administered intravenously to 57 patients with 60 episodes of arrhythmia (21 supraventricular and 39 ventricular) as a 2 mg/kg bolus." | 3.65 | The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate. ( Deano, DA; Ehsani, AI; Mautner, RK; Rosen, KM; Sherman, RH; Wu, D, 1977) |
| "We evaluated the electrophysiological mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline in seven patients, pilsicainide in two, and disopyramide in two, and procainamide in three) in the induction of orthodromic atrioventricular re-entrant tachycardia (AVRT)." | 2.68 | Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia. ( Fujiki, A; Inoue, H; Tani, M; Yoshida, S, 1996) |
| "Disopyramide (1,7 mg/kg) was administered in 10 patients." | 2.64 | [Electrophysiological effects of the antiarrhythmia agents disopyramide and propafenone on human heart conduction system]. ( Both, A; Breithardt, G; Seipel, L, 1975) |
| "Disopyramide was first infused intravenously at 1 mg kg-1 for 5 min followed by a continuous infusion at 0." | 1.28 | Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White syndrome. ( Aihara, N; Kamakura, S; Kurita, T; Matsuhisa, M; Ohe, T; Shimizu, W; Shimomura, K; Takaki, H, 1992) |
| "In four patients with the WPW syndrome and five with VVI pacing, the phase difference between the posterolateral wall of the left ventricle (LV) and the right ventricular apex correlated significantly with the activation time difference between these two regions as assessed by endocardial electrograms (r = 0." | 1.27 | [Gated blood pool imaging in the diagnosis and management of arrhythmia]. ( Kato, R; Kawai, N; Matsushima, H; Okada, M; Sotobata, I; Tanahashi, Y; Yamamoto, S, 1985) |
| "In the manifest WPW syndrome, disopyramide or aprindine was indicated especially for patients with the accessory pathways of the short antegrade refractory period, because these drugs lengthened the refractory period of the accessory pathways." | 1.27 | Usefulness of invasive and non-invasive electrophysiologic studies in the selection of antiarrhythmic drugs for the patients with paroxysmal supraventricular tachyarrhythmia. ( Hiejima, K; Hirao, K; Kubo, I; Moroi, Y; Satake, S; Suzuki, F, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (74.19) | 18.7374 |
| 1990's | 7 (22.58) | 18.2507 |
| 2000's | 1 (3.23) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prystowsky, EN | 2 |
| Tajima, T | 1 |
| Dohi, Y | 1 |
| Smolenskiĭ, VS | 1 |
| Fomina, IG | 1 |
| Iankin, VV | 1 |
| Aliab'eva, IM | 1 |
| Kulikova, LA | 1 |
| Jackman, WM | 1 |
| Friday, KJ | 1 |
| Scherlag, BJ | 1 |
| Dehning, MM | 1 |
| Schechter, E | 1 |
| Reynolds, DW | 1 |
| Olson, EG | 1 |
| Berbari, EJ | 1 |
| Harrison, LA | 1 |
| Lazzara, R | 1 |
| Chia, BL | 1 |
| Choo, MH | 1 |
| Tan, AT | 1 |
| Ee, B | 1 |
| Kerr, CR | 1 |
| Smith, WM | 1 |
| Cook, L | 1 |
| Gallagher, JJ | 1 |
| Neumann, G | 1 |
| Grube, E | 1 |
| Funke, H | 1 |
| Bauernfeind, RA | 1 |
| Swiryn, SP | 1 |
| Strasberg, B | 1 |
| Palileo, E | 1 |
| Scagliotti, D | 1 |
| Rosen, KM | 2 |
| Grosu, AA | 2 |
| Malakhov, VI | 1 |
| Smetnev, AS | 1 |
| Matsuda, H | 1 |
| Konishi, T | 1 |
| Matsuyama, E | 1 |
| Tamamura, T | 1 |
| Kawai, C | 1 |
| Hasegawa, J | 1 |
| Mashiba, H | 1 |
| Bobrov, VA | 1 |
| Frolov, AI | 1 |
| Mitchenko, EI | 1 |
| Galichansky, IV | 1 |
| Fujiki, A | 1 |
| Tani, M | 1 |
| Yoshida, S | 1 |
| Inoue, H | 1 |
| Wolff, GS | 1 |
| Abbi, M | 1 |
| Kriplani, A | 1 |
| Singh, B | 1 |
| Niwano, S | 1 |
| Kitano, Y | 1 |
| Moriguchi, M | 1 |
| Izumi, T | 1 |
| Dreifus, LS | 1 |
| Spurrell, RA | 1 |
| Thorburn, CW | 1 |
| Camm, J | 1 |
| Sowton, E | 1 |
| Deuchar, DC | 1 |
| Forester, D | 1 |
| Hoffmann, RM | 1 |
| Bennett, DH | 1 |
| Deano, DA | 1 |
| Wu, D | 1 |
| Mautner, RK | 1 |
| Sherman, RH | 1 |
| Ehsani, AI | 1 |
| Seipel, L | 1 |
| Breithardt, G | 1 |
| Both, A | 1 |
| Perederiĭ, VG | 1 |
| Nikitin, AV | 1 |
| Zemskov, AM | 1 |
| Gusmanov, VA | 1 |
| Shimizu, W | 1 |
| Ohe, T | 1 |
| Kurita, T | 1 |
| Takaki, H | 1 |
| Aihara, N | 1 |
| Kamakura, S | 1 |
| Matsuhisa, M | 1 |
| Shimomura, K | 1 |
| Yamamoto, S | 1 |
| Kawai, N | 1 |
| Okada, M | 1 |
| Matsushima, H | 1 |
| Kato, R | 1 |
| Sotobata, I | 1 |
| Tanahashi, Y | 1 |
| Fujimura, O | 1 |
| Klein, GJ | 2 |
| Sharma, AD | 2 |
| Yee, R | 2 |
| Szabo, T | 1 |
| Guiraudon, G | 1 |
| Bajaj, A | 1 |
| Patel, JS | 1 |
| Satake, S | 1 |
| Hiejima, K | 1 |
| Moroi, Y | 1 |
| Hirao, K | 1 |
| Kubo, I | 1 |
| Suzuki, F | 2 |
3 reviews available for disopyramide and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
Pharmacologic therapy of tachyarrhythmias in patients with Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Ajmaline; Amiodarone; Anilides; Aprindine; Atr | 1983 |
Unexplained syncope: clinical management.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Behavior Ther | 1997 |
[Disopyramide phosphate: the electrophysiological mechanisms of its anti-arrhythmia action and its use in clinical practice].
Topics: Animals; Arrhythmias, Cardiac; Atrioventricular Node; Disopyramide; Dogs; Electrophysiology; Heart; | 1985 |
2 trials available for disopyramide and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
Electrophysiologic mechanisms of adverse effects of class I antiarrhythmic drugs (cibenzoline, pilsicainide, disopyramide, procainamide) in induction of atrioventricular re-entrant tachycardia.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Disopyramide; Electrophysiology; Female; Heart Cond | 1996 |
[Electrophysiological effects of the antiarrhythmia agents disopyramide and propafenone on human heart conduction system].
Topics: Adult; Anti-Arrhythmia Agents; Bundle of His; Disopyramide; Electric Stimulation; Electrocardiograph | 1975 |
26 other studies available for disopyramide and Wolff-Parkinson-White Syndrome
| Article | Year |
|---|---|
Electrophysiological effects of intravenous disopyramide phosphate on the Wolff-Parkinson-White syndrome.
Topics: Adult; Bundle of His; Cardiac Pacing, Artificial; Disopyramide; Dose-Response Relationship, Drug; El | 1982 |
[Rare complication in disopyramide treatment].
Topics: Adult; Blood Pressure; Disopyramide; Electrocardiography; Female; Heart Rate; Humans; Wolff-Parkinso | 1984 |
Direct endocardial recording from an accessory atrioventricular pathway: localization of the site of block, effect of antiarrhythmic drugs, and attempt at nonsurgical ablation.
Topics: Adult; Anti-Arrhythmia Agents; Atrioventricular Node; Cardiac Pacing, Artificial; Disopyramide; Ebst | 1983 |
Atrial flutter in Wolff-Parkinson-White syndrome responding to intravenous disopyramide.
Topics: Aged; Atrial Flutter; Disopyramide; Electrocardiography; Female; Humans; Infusions, Parenteral; Wolf | 1984 |
Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Adolescent; Adult; Atrial Fibrillation; Disopyramide; Electrocardiography; Fem | 1982 |
[The value of antitachycardia pacemaker therapy in patients with Wolff-Parkinson-White syndrome].
Topics: Anti-Arrhythmia Agents; Bundle of His; Digitalis Glycosides; Disopyramide; Electrocardiography; Huma | 1983 |
Electrophysiologic drug testing in prophylaxis of sporadic paroxysmal atrial fibrillation: technique, application, and efficacy in severely symptomatic preexcitation patients.
Topics: Administration, Oral; Adolescent; Adult; Aprindine; Atrial Fibrillation; Cardiac Pacing, Artificial; | 1982 |
[Electrophysiological action of disopyramide].
Topics: Adolescent; Adult; Atrial Fibrillation; Cardiac Catheterization; Disopyramide; Drug Evaluation; Elec | 1982 |
Combined effect of verapamil and disopyramide on induction of circus movement tachycardia in patients with pre-excitation.
Topics: Adolescent; Adult; Atrioventricular Node; Disopyramide; Drug Synergism; Female; Heart Conduction Sys | 1981 |
Transient sexual dysfunction observed during antiarrhythmic therapy by long-acting disopyramide in a male Wolff-Parkinson-White patient.
Topics: Disopyramide; Erectile Dysfunction; Humans; Male; Middle Aged; Time Factors; Wolff-Parkinson-White S | 1994 |
Comparative analysis of electrophysiologic effect of metoprolol and disopyramide, acting alone or in combination in patients with supraventricular tachycardia and Wolff-Parkinson-White syndrome.
Topics: Adult; Disopyramide; Drug Therapy, Combination; Electrophysiology; Female; Humans; Male; Metoprolol; | 1994 |
Preterm labor and accidental hemorrhage after disopyramide therapy in pregnancy. A case report.
Topics: Abruptio Placentae; Adult; Anti-Arrhythmia Agents; Disopyramide; Electrocardiography; Female; Humans | 1999 |
Transient appearance of antegrade conduction via an AV accessory pathway caused by atrial fibrillation in a patient with intermittent Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Electrocardiography | 2000 |
Clinical studies of Norpace (Part X).
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes | 1975 |
Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Atrial Fibrillation; Atrioventricular Node; Cardiac Complexes, Premature; Child; | 1975 |
Treatment of arrhythmias in the Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Atrial Fibrillation; Disopyramide; Humans; Injections, Intravenous; Lidocaine; | 1979 |
Wolff-Parkinson-White syndrome. Evaluation of a potentially life threatening situation.
Topics: Adult; Atrial Fibrillation; Digoxin; Disopyramide; Humans; Male; Organophosphorus Compounds; Refract | 1978 |
Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Disopyramide; Female; Heart Ventricles; Huma | 1978 |
The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Disopy | 1977 |
[The possible significance of immunological disorders in the pathogenesis of paroxysmal supraventricular tachycardia in patients with the Wolff-Parkinson-White syndrome].
Topics: Adjuvants, Immunologic; Adult; Disease Susceptibility; Disopyramide; Drug Therapy, Combination; Fema | 1992 |
Effects of a combination of disopyramide and mexiletine on the anterograde accessory pathway conduction in patients with Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Cardiac Pacing, Artificial; Disopyramide; Dose-Response Relationship, Dr | 1992 |
[Gated blood pool imaging in the diagnosis and management of arrhythmia].
Topics: Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiac Output; Disopyramide; Electrocardiograph | 1985 |
Acute effect of disopyramide on atrial fibrillation in the Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Atrial Fibrillation; Disopyramide; Electrocardiography; Female; Humans; Male; Mid | 1989 |
Sensitivity and specificity of invasive and noninvasive testing for risk of sudden death in Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adult; Aged; Atrial Fibrillation; Child; Death, Sudden; Disopyramide; Electrocardiograph | 1987 |
Wolff-Parkinson and White syndrome. Clinical presentation and management.
Topics: Adult; Atrial Fibrillation; Disopyramide; Electrocardiography; Female; Humans; Male; Middle Aged; Wo | 1986 |
Usefulness of invasive and non-invasive electrophysiologic studies in the selection of antiarrhythmic drugs for the patients with paroxysmal supraventricular tachyarrhythmia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Bundle of His; Disopyramide; | 1985 |